NEW YORK, Aug. 03, 2020 (GLOBE NEWSWIRE) — Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its second quarter 2020 financial results prior to market open on Monday, August 10, 2020. The announcement will be followed by a conference call and audio webcast hosted by Intercept management at 8:30 a.m. ET to discuss the results.
The conference call will be available on the investor page of our website at http://ir.interceptpharma.com or by calling (855) 232-3919 (toll-free domestic) or (315) 625-6894 (international) passcode 5073644. Archived webcasts will be available on Intercept’s website for approximately two weeks.
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada. For more information, please visit www.interceptpharma.com or connect with the company on Twitter and LinkedIn.
For more information about Intercept, please contact:
Investor inquiries: [email protected]
Media inquiries: [email protected]
Source: Intercept Pharmaceuticals, Inc.
- Home BancShares, Inc. Announces Increasein Fourth Quarter Cash Dividend - October 21, 2020
- Oak Valley Bancorp Reports 3rd Quarter Results - October 21, 2020
- Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against GoHealth, Wrap Technologies, Golar LNG, and BioMarin Pharmaceuticals and Encourages Investors to Contact the Firm - October 21, 2020